Price T Rowe Associates Inc. MD Boosts Stock Position in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Price T Rowe Associates Inc. MD increased its stake in DENTSPLY SIRONA Inc. by 11.3%, owning approximately 13.96 million shares valued at $208.59 million as of the latest SEC filing.
• DENTSPLY SIRONA Inc. reported a quarterly EPS of $0.52, slightly surpassing analysts' estimates and showing a 4.9% decline in revenue year-over-year.
• The company announced a $0.16 quarterly dividend, reflecting a 4.4% dividend yield, with the payout date set for October 10th.

Price T Rowe Associates Inc. MD raised its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 11.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,961,759 shares of the medical instruments supplier's stock after purchasing an additional 1,412,517 shares during the period. Price T Rowe Associates Inc. MD owned 7.01% of DENTSPLY SIRONA worth $208,590,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in DENTSPLY SIRONA in the first quarter valued at about $25,000. Colonial Trust Co SC purchased a new position in DENTSPLY SIRONA in the fourth quarter valued at about $26,000. Brooklyn Investment Group purchased a new position in DENTSPLY SIRONA in the first quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its stake in DENTSPLY SIRONA by 8,003.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,269 shares of the medical instruments supplier's stock valued at $34,000 after purchasing an additional 2,241 shares during the last quarter. Finally, True Wealth Design LLC grew its stake in DENTSPLY SIRONA by 866.7% in the fourth quarter. True Wealth Design LLC now owns 2,175 shares of the medical instruments supplier's stock valued at $41,000 after purchasing an additional 1,950 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on XRAY. UBS Group dropped their price target on DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company dropped their price target on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Friday, August 8th. Needham & Company LLC restated a "hold" rating on shares of DENTSPLY SIRONA in a research note on Monday, July 21st. Piper Sandler dropped their price target on DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Finally, Barrington Research dropped their price target on DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Two analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, DENTSPLY SIRONA currently has a consensus rating of "Hold" and a consensus price target of $18.64.

DENTSPLY SIRONA Trading Up 5.5%

DENTSPLY SIRONA stock opened at $14.66 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.69 and a debt-to-equity ratio of 1.13. DENTSPLY SIRONA Inc. has a 52 week low of $12.16 and a 52 week high of $27.48. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -3.09, a price-to-earnings-growth ratio of 0.91 and a beta of 0.94. The stock has a 50-day moving average price of $15.27 and a 200 day moving average price of $15.50.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The firm had revenue of $936.00 million during the quarter, compared to the consensus estimate of $929.67 million. During the same quarter in the previous year, the company posted $0.49 earnings per share. The company's revenue was down 4.9% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. Sell-side analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 10th. Investors of record on Friday, September 26th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.4%. DENTSPLY SIRONA's payout ratio is -13.50%.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.